TFA
VKTX icon

Toth Financial Advisory’s Viking Therapeutics VKTX Stock Holding History

Toth Financial Advisory’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$13K Hold
400
– – ﹤0.01% 563
2026
Q2 		$15.6K Hold
400
– – ﹤0.01% 534
2026
Q1 		$13K Buy
400
+200
+100% +$6.43K ﹤0.01% 531
2025
Q4 		$7.04K Hold
200
– – ﹤0.01% 602
2025
Q3 		$5.26K Hold
200
– – ﹤0.01% 605
2025
Q2 		$5.3K Hold
200
– – ﹤0.01% 553
2025
Q1 		$4.83K Buy
+200
New +$6.32K ﹤0.01% 527

Other funds holding VKTX

FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
NWMP
Noble Wealth Management PBC Greenwood Village, Colorado $223M AUM 7.64% 1-Year Est. Return
BFS
Burkett Financial Services Rock Hill, South Carolina $331M AUM 14.93% 1-Year Est. Return
GA
GoalVest Advisory New York $578M AUM 17.41% 1-Year Est. Return
PP
Paladin Partners Hartland, Wisconsin $162M AUM 13.31% 1-Year Est. Return
WETS
Wealth Enhancement Trust Services Sioux Falls, South Dakota $937M AUM 18.56% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return
PS
Planning Strategies Lancaster, Pennsylvania $169M AUM

Toth Financial Advisory's VKTX Position: Q3 2026 in Review

Toth Financial Advisory held its Viking Therapeutics (VKTX) position steady in Q3 2026 at 400 shares worth $13K. The position accounts for ﹤0.01% of the portfolio, ranked #563.

Toth Financial Advisory first reported a position in VKTX in Q1 2025 and has held it in 7 quarters since. The position peaked at $15.6K in Q2 2026. 11 funds tracked by Wall St. Rank hold VKTX as of Q3 2026.

  • Toth Financial Advisory held 400 shares of Viking Therapeutics worth $13K as of Q3 2026.
  • Toth Financial Advisory left its Viking Therapeutics share count unchanged in Q3 2026.
  • Viking Therapeutics made up ﹤0.01% of Toth Financial Advisory's portfolio in Q3 2026, its #563 holding.
  • Toth Financial Advisory first reported a position in Viking Therapeutics in Q1 2025 and has held it in 7 quarters since.
  • Toth Financial Advisory's Viking Therapeutics position peaked at $15.6K in Q2 2026.
  • 11 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2026.

Based on Toth Financial Advisory's 13F filing for Q3 2026, filed 8 Oct 2026.